Phase 3 plaque Clinical Trials
17 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–17 of 17 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL168 enrolled50 locationsNCT06425549
Recruiting
Phase 3
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Plaque Psoriasis
Takeda110 enrolled40 locationsNCT07250802
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled357 locationsNCT07116967
Recruiting
Phase 3
Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia
InflammationCommunity-Acquired Pneumonia (CAP)Inflammation Plaque, Atherosclerotic
Ottawa Heart Institute Research Corporation168 enrolled1 locationNCT06710080
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Bristol-Myers Squibb366 enrolled120 locationsNCT06979453
Recruiting
Phase 3
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Psoriatic ArthritisModerate to Severe Plaque Psoriasis
UCB Biopharma SRL90 enrolled16 locationsNCT06506916
Recruiting
Phase 3
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
InventisBio Co., Ltd477 enrolled1 locationNCT07326813
Recruiting
Phase 3
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.383 enrolled46 locationsNCT06842199
Recruiting
Phase 3
Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.
plaque
Colgate Palmolive135 enrolled1 locationNCT07398846
Recruiting
Phase 3
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Plaque Psoriasis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.537 enrolled55 locationsNCT07357831
Recruiting
Phase 3
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
InventisBio Co., Ltd390 enrolled1 locationNCT07130604
Recruiting
Phase 3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Bristol-Myers Squibb153 enrolled63 locationsNCT04772079
Recruiting
Phase 3
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Coronary Artery DiseaseLipidemiaPlaque, Atherosclerotic
NewAmsterdam Pharma300 enrolled1 locationNCT06305559
Recruiting
Phase 3
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
Plaque Psoriasis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.189 enrolled31 locationsNCT06648772
Recruiting
Phase 2Phase 3
Role of Kefir Mouth Wash in Oral Health Status Amelioration
Plaque-induced gingivitisHalitosisOral Disease
Al-Mustansiriyah University60 enrolled1 locationNCT06900881
Recruiting
Phase 3
Efficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.
HalitosisPeridontal DiseaseBleeding Gum+2 more
Al-Mustansiriyah University54 enrolled1 locationNCT06882564
Active
Phase 3Phase 4
An Open-Label, Multicentre Study to Evaluate the Duration of Clinical Remission of Two Courses of Weekly Intramuscular administration of AMEVIVE (alefacept) by evaluating the time to retreatment with AMEVIVE or an alternative systemic therapy in patients with chronic plaque psoriasis in the context of standard dermatological practice
Chronic plaque psoriasis
Biogen Idec100 enrolled1 locationACTRN12605000295640